High-Tech Gründerfonds

High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.

Daniela Bach

Principal and Authorized Signatory

Kay G. Balster

Senior Investment Manager

Jens Baumgärtner

Principal and Authorized Signatory

Gernot Berger

Investor

Kilian von Berlichingen

Investor

Anke Cassing

Principal

Tanja Emmerling

Partner

Caroline Fichtner

Senior Investment Manager

Yann Fiebig

Investment Manager

Alexander von Frankenberg

Managing Director and Founder

Bernd Goergen

Partner

Stefanie Grüter

Partner, Communications and Relations

Gregor Haidl

Principal / Authorised Signatory

Frank Hensel

Senior Investment Manager

Olaf Joeressen

Senior Investment Manager

Markus Kressmann

Partner

Maurice Kügler

Investment Manager

Klaus Lehmann

Senior Investment Manager

Dominik Lohle

Senior Investment Manager

Torsten Löffler

Principal ppa. - DeepTech Future Fonds

Fabian Mohr

Investor

Martin Möllmann

Investment Manager

Axel Nitsch

Investment Manager

Andreas Olmes

Principal and Authorized Signatory

Katharina Peters

Investment Manager

Tilmann Petersen

Investment Manager

Claudia Raber

Partner

Nikolaus Raupp

Investor

Frank Reinecke

Partner

Guido Schlitzer

Managing Director

Ulrich Schmitt

Principal

Romy Schnelle

Partner

Tobias Schulz

Principal and Authorized Signatory

Katharina Severin

Investment Manager

Niels Sharman

Investor

Esko Stahl

Investment Manager

Björn Sykora

Principal and Authorized Signatory

Angelika Vlachou

Partner

Johannes Weber

Principal

Marco Winzer

Partner

Julian Zachmann

Investor

Christian Ziach

Principal and Authorized Signatory

Markus Kückelhaus Ph.D

Partner, Industrial Tech Team

Past deals in Nanotechnology

Nia Health

Seed Round in 2023
Nia Health is a medical software developer focused on supporting individuals with chronic skin conditions, particularly atopic dermatitis. Its primary product, the Nia eczema app, delivers personalized, clinically validated information aimed at alleviating the burden and stigma associated with these conditions. The platform is designed to empower parents of children with eczema by providing them with effective treatment options and enhancing their confidence in managing the disease. By addressing inefficiencies in the healthcare system, Nia Health's solutions aim to lower costs while improving access to necessary medical resources for patients.

GS Bavaria

Seed Round in 2022
GS Bavaria specializes in the manufacturing of industrial-scale nano-sized carbide powders, focusing on environmentally friendly nanomaterials. The company utilizes a revolutionary bioleaching extraction process that transforms hard metal scrap into tungsten and tungsten carbide nanoparticles. This innovative method not only enables cost-efficient production but also minimizes energy consumption, making it a sustainable alternative in the industry. By harnessing the capabilities of bacteria, GS Bavaria positions itself to expand its processes to other metals in the future, offering unique materials and functional additives to clients across various sectors.

Noscendo

Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Their diagnostic procedures utilize Next Generation Sequencing (NGS) technology, enabling intensive care clinicians to detect bacteria, fungi, viruses, and parasites present in patients' blood. Noscendo employs proprietary algorithms to evaluate the significance of each identified pathogen, thereby enhancing the accuracy and effectiveness of infection management in clinical settings.

Nebula Biocides

Seed Round in 2021
Nebula Biocides specializes in the development of innovative disinfection solutions aimed at effectively combating persistent bacterial spores and resistant viruses. The company focuses on creating application-oriented disinfection products that provide reliable protection against infections in various settings. Their offerings include advanced disinfection systems and devices designed to ensure comprehensive microbial control, addressing the challenges posed by stubborn pathogens. Through these solutions, Nebula Biocides aims to enhance health safety for users by delivering effective disinfection that can be utilized in diverse environments.

Qnami

Series A in 2021
Qnami AG manufactures non-invasive sensors. Its products include ProteusQ, non-invasive magnetic imaging microscope; and Quantum Diamond, which includes Quantilevers MX, diamond probes containing a single NV for high resolution magnetic imaging, and NV diamond membranes, ready-to-use diamond with NV centers. Its applications are multiferroic antiferromagnet, antiferromagnetic ram, microwave imaging, magnetic nanomemories, and superconductivity. Qnami AG was founded in 2017 and is based in Basel, Switzerland.

PreComb

Seed Round in 2021
PreComb is a technology company focused on enhancing cancer treatment outcomes through innovative solutions tailored for difficult-to-treat cancers. The company has developed a 3D drug testing technology that utilizes automated microtumor-based profiling for in vitro cancer diagnosis. This technology enables clinical institutions to conduct on-site evaluations, allowing for the functional assessment of various cancer drugs, combinations, and concentrations using patient-derived micro-tumors. By optimizing the selection of therapies, PreComb aims to improve success rates in cancer treatment and ultimately enhance the quality of life for patients.

Delft Circuits

Venture Round in 2021
Delft Circuits specializes in the manufacture of cryogenic circuits designed for scientific instrumentation, quantum computing, and astronomy. The company provides custom-engineered superconducting circuits and cryogenic instrumentation that feature ultra-low thermal conductance and scalable cryogenic cabling. This technology enables researchers to conduct experiments and develop applications in quantum technologies by offering tailored cryogenic circuit packaging to meet specific requirements. Delft Circuits is committed to supporting quantum engineers and the broader industry in making advancements in quantum technologies.

HighLine Technology

Pre Seed Round in 2021
Developer of parallel dispensing technology designed to reduce material consumption in the PV (Photovoltaics ) industry. The company's technology is used to apply front metal contacts onto solar cells and can be integrated into conventional production lines for silicon solar cells, replacing the screen printing process normally used for the front-side metal contacts, enabling clients to save resources, increasing the electricity yield and increasing throughput.

Actitrexx

Series A in 2021
Developer of a cell therapy technology designed for the treatment of patients after a stem cell transplant to prevent rejection reactions. The company's technology focuses on the development of clinical testing of cell therapeutics for the suppression of transplant rejection and autoimmunity and the portfolio of cell therapy, enabling patients to prevent the fatal consequences of rejection, significantly improving their quality of life, and also opening up to many therapy options.

Noscendo

Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Their diagnostic procedures utilize Next Generation Sequencing (NGS) technology, enabling intensive care clinicians to detect bacteria, fungi, viruses, and parasites present in patients' blood. Noscendo employs proprietary algorithms to evaluate the significance of each identified pathogen, thereby enhancing the accuracy and effectiveness of infection management in clinical settings.

Scipio Bioscience

Series A in 2020
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.

Qnami

Seed Round in 2019
Qnami AG manufactures non-invasive sensors. Its products include ProteusQ, non-invasive magnetic imaging microscope; and Quantum Diamond, which includes Quantilevers MX, diamond probes containing a single NV for high resolution magnetic imaging, and NV diamond membranes, ready-to-use diamond with NV centers. Its applications are multiferroic antiferromagnet, antiferromagnetic ram, microwave imaging, magnetic nanomemories, and superconductivity. Qnami AG was founded in 2017 and is based in Basel, Switzerland.

Belyntic

Seed Round in 2019
Belyntic is a biotechnology company focused on advancing peptide purification and vaccine development. It has developed a purification kit that utilizes its innovative Catch & Release Technology, allowing for HPLC-free purification of chemically synthesized peptides. This technology aims to streamline and improve the peptide purification process. Additionally, Belyntic is engaged in the creation of novel vaccines designed to prevent viral diseases, bacterial infections, and cancer. The company offers ready-to-use research kits and engineered vaccines that activate T-cell immune responses, demonstrating significant potential in enhancing vaccine efficacy. By integrating artificial intelligence in its processes, Belyntic aims to identify pathogen-specific epitopes for self-adjuvant nano vaccine structures, supporting clients in the research, development, and production of peptide therapeutics for better health outcomes.

Pantherna Therapeutics

Seed Round in 2019
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.

DyNAbind

Seed Round in 2019
DyNAbind GmbH, based in Dresden, Germany, is a biotech company specializing in drug discovery technologies using Dynamic DNA-Encoded Library (D-DEL) systems. Founded in 2015, the company focuses on developing regenerable biosensor technologies and offers services in DNA-encoded chemical library synthesis, selection, and decoding. DyNAbind's proprietary innovations enhance the drug discovery process by providing valuable insights into drug targetability and structure-activity relationship (SAR) analysis. The platform is designed to integrate seamlessly with fragment-based discovery methodologies, facilitating the identification of high-quality medicinal chemistry starting points for various protein targets. By expanding chemical space coverage, DyNAbind aims to support the healthcare industry in achieving more effective drug development outcomes.

NAVAN Technologies

Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company focuses on developing and commercializing its proprietary NanoStraw platform technology, which facilitates direct access to the cytosol of cells. This innovative technology addresses a significant challenge in the field of cell and gene therapies by enabling the efficient and gentle delivery of various materials into difficult-to-transfect cells. Through its NanoStraw platform, NAVAN aims to enhance the capabilities of researchers in their efforts to advance therapeutic solutions.

denovoMATRIX

Seed Round in 2018
denovoMATRIX GmbH, founded in 2018 and based in Dresden, Germany, specializes in the development and manufacturing of biomimetic coatings specifically designed for stem cell culture. The company's flagship products include screenMATRIX, a coating that enhances the adhesion, differentiation, migration, and organization of stem cells, and myMATRIX, a customized tissue cultureware microenvironment that supports the growth of stem cells and primary cells in serum-free media. These innovative products are utilized in various applications, including stem cell research, tissue modeling, and cell-based therapies, providing researchers with essential tools to advance their work and explore potential medical applications.

Scipio Bioscience

Seed Round in 2017
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.

Ferroelectric Memory GmbH

Seed Round in 2017
Ferroelectric Memory GmbH provides embedded nonvolatile memory solutions (eNVM) based on ferroelectric hafnium oxide (FE-HfO2). It provides its technology to semiconductor manufacturers and fabless companies to utilize in fabs and chip designs. The company is based in Dresden, Germany.

Numaferm

Seed Round in 2017
NUMAFERM challenges this paradigm. We have developed a reliable, cost-efficient manufacturing process that enables the reduction of production costs dramatically (up to 1000x). How is it possible? Our process is based on a well-designed microorganism that converts simple nutrients to peptides. It is the first-in-place bioprocess that serves as a reliable platform for the production of peptides; independent of their sequence, length or functionality.

Thermosome

Seed Round in 2016
Thermosome GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing innovative drug candidates for cancer treatment. The company utilizes a proprietary drug delivery technology that operates through a mechanism known as intravascular drug release. This platform aims to enhance the efficacy and reduce the side effects of chemotherapy, particularly for patients with locally advanced solid tumors. Thermosome's lead product is currently in the final pre-clinical development stage, and the company has built its foundation on promising preclinical results obtained from research conducted at the Max Planck Institute for Biophysical Chemistry and the University Hospital of Ludwig-Maximilians-Universität Munich. Since commencing its operational activities in late 2015, Thermosome has been dedicated to advancing treatment options for cancer patients through targeted therapeutic approaches.

SeNostic

Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.

Venneos

Seed Round in 2015
Venneos GmbH, founded in 2014 in Stuttgart, Germany, is a high-tech startup that specializes in developing a silicon chip-based imaging system for the label-free analysis of biological cells. The company's flagship product, the CAN-Q, utilizes a technology known as CAN-Spectroscopy, which enables researchers to observe cellular changes, particularly in areas such as cell adhesion, that are not detectable with conventional methods. This innovative imaging system provides valuable insights for applications in tumor biology, immunology, and pharmacology, serving customers in both academia and the pharmaceutical and biotechnology sectors. As a spin-off from the Max Planck Society, Venneos aims to advance the capabilities of biological analysis through its cutting-edge technology.

i3 Membrane

Seed Round in 2014
i3 membrane will assist you creating new membranes for next life science. The qualities inertness, flexibility, durability and conductivity of i3 membranes are predestinated to meet current and future challenges to ensure success in your research, development and production.

microDimensions

Seed Round in 2014
microDimensions GmbH, based in Munich, Germany, specializes in developing software solutions for the processing, analysis, and visualization of microscopic image data, particularly in the field of digital pathology. Founded in 2011, the company offers products such as Voloom, an automated software for 3D reconstruction and analysis of histology specimens, and Zoom, a viewer for rapid visualization of whole slide images. Their software aids researchers in pharmaceutical, biotechnology, and pathology sectors with various histological applications, including cell counting and tumor border computation. microDimensions also provides reconstruction and analysis services, ensuring that their solutions can be seamlessly integrated into existing workflows. The company's commitment to creating efficient algorithms and high-quality standards enhances the speed and accuracy of histological assessments for pathologists.

Rodos BioTarget

Venture Round in 2013
Rodos BioTarget GmbH is a biopharmaceutical company based in Hanover, Germany, founded in 2008. The company specializes in developing advanced drug delivery technologies, notably its patented TargoSphere platform. This nanocarrier system is designed to deliver a variety of therapeutic agents directly to antigen-presenting cells, thereby enhancing the immune response against infectious diseases caused by viruses, such as Hepatitis C and HIV, as well as bacterial infections like Tuberculosis and MRSA. Rodos BioTarget also offers TargoBiotics, which includes antibiotics for intracellular treatment, and TargoVir for viral infections. Additionally, the TargoSphere technology has potential applications in managing chronic inflammation, cancer, allergies, and autoimmune diseases by addressing imbalances in immune responses. The company's innovations aim to improve drug stability, biodistribution, and therapeutic efficacy.

Notion Systems

Seed Round in 2013
Notion Systems GmbH is a German company located in Schwetzingen that specializes in the development, manufacturing, and sale of advanced printing and automation equipment. The company produces high-precision inkjet printers designed for the precise application of technical inks, as well as laser treatment systems that offer solutions for ablation, structuring, drilling, and cutting. Notion Systems also focuses on custom-made automation solutions, including positioning systems equipped with integrated image processing and alignment capabilities. Their products cater to various technical applications, emphasizing quality and precision in manufacturing processes.

SOPAT

Series A in 2013
SOPAT is specialized in the analysis of particulate systems. Our team develops and markets an innovative particle measurement technology for real-time analysis of multi-phase systems.

InnoCyte

Series A in 2012
InnoCyte - Technologies for automated Cell Culture. They have the strong belief that automated cell culture could be of inestimable value for cell processing in labs all over the world. InnoCyte brings automated cell culture to the masses - within a benchtop designed, reliable and affordable device.

JeNaCell

Seed Round in 2012
JeNaCell GmbH, founded in 2012 and based in Jena, Germany, specializes in biotechnology by developing and manufacturing bio-technologically derived cellulose. The company has patented a unique technology for the continuous production of high-performance biomaterials featuring natural nanostructures. These materials have a defined shape and controllable structural design, allowing clients to create innovative products across various sectors, including medicine, cosmetics, technology, and pharmaceuticals. JeNaCell's solutions are particularly beneficial in medical applications, helping to protect skin from chronic wounds and enhancing treatments in aesthetic dermatology.

Microstim

Venture Round in 2011
Microstim GmbH develops a tissue and function maintaining implantable myostimulator designed to assist the heart. Particular strengths of Microstim GmbH are the microcontroller acquisition and processing of data, control of cardiac and muscle stimulator impulses, and wireless “in-body”-communication. At the national business plan contest “Science4Life” in 2008, Microstim GmbH was one of ten winners in the concept phase category.

Lipocalyx

Seed Round in 2011
Lipocalyx GmbH, a Wolfen, Germany-based newly founded company focused on development of transfection reagents for siRNA based on innovative polymers.

NonWoTecc Medical

Series B in 2011
NonWoTecc GmbH was founded with the financial support of High-Tech Gründerfond (HTGF) and Rheinland Venture Capital Fond (RVC) in February of 2007. The goal was to develop a newly designed vascular prosthesis with improved biocompatible and bio-stable properties. NonWoTecc GmbH was one of only seven companies which received a commitment for financial support from HTGF in 2006.

SIRION BIOTECH

Venture Round in 2011
Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing. The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector. The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.

Heppe Medical Chitosan

Series B in 2010
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers primarily for the cosmetic and pharmaceutical sectors. Founded in 2005, the company focuses on chitin, chitosan, and their derivatives, providing high-quality raw materials that adhere to Good Manufacturing Practice (GMP) standards. In addition to conventional chitin and chitosan products, Heppe Medical Chitosan also creates nanoparticulate forms of these biopolymers, catering to diverse applications within its target industries. The company was formerly known as Katja Heppe Medical Chitosan and adopted its current name in 2006.

Nanda Technologies

Venture Round in 2010
Nanda Technologies was founded in 2006 in Munich. They are an international team of experienced engineers and managers from the semiconductor/high-tech industry. They are in the process of bringing their new product to the market by working together with selected lead customers.

H.C. Carbon GmbH

Seed Round in 2009
H.C. Carbon develops and distributes a range of carbon- and dispersion-based products to its clients. The company’s product portfolio consists of conductive additives, flame retardants, insulating, shielding, and lubricants. H.C. Carbon was founded in 2009 by Werner Handl and is based in Germany.

Intana BioScience

Seed Round in 2009
Intana Bioscience GmbH is a customized assay development, screening and target validation company that uses fluorescence cross-correlation spectroscopy. It offers its users with fast assay development time, physiological measurement conditions, and comprehensive readouts. Technologies used in the company are fluorescence correlation spectroscopy, fluorescence cross-correlation spectroscopy, and FCS and FCCS measurements. Intana Bioscience GmbH is a Germany-based company that was founded in 2008 by Stefan Hannus and Frank Becker.

Rodos BioTarget

Seed Round in 2009
Rodos BioTarget GmbH is a biopharmaceutical company based in Hanover, Germany, founded in 2008. The company specializes in developing advanced drug delivery technologies, notably its patented TargoSphere platform. This nanocarrier system is designed to deliver a variety of therapeutic agents directly to antigen-presenting cells, thereby enhancing the immune response against infectious diseases caused by viruses, such as Hepatitis C and HIV, as well as bacterial infections like Tuberculosis and MRSA. Rodos BioTarget also offers TargoBiotics, which includes antibiotics for intracellular treatment, and TargoVir for viral infections. Additionally, the TargoSphere technology has potential applications in managing chronic inflammation, cancer, allergies, and autoimmune diseases by addressing imbalances in immune responses. The company's innovations aim to improve drug stability, biodistribution, and therapeutic efficacy.

Microstim

Seed Round in 2009
Microstim GmbH develops a tissue and function maintaining implantable myostimulator designed to assist the heart. Particular strengths of Microstim GmbH are the microcontroller acquisition and processing of data, control of cardiac and muscle stimulator impulses, and wireless “in-body”-communication. At the national business plan contest “Science4Life” in 2008, Microstim GmbH was one of ten winners in the concept phase category.

Heppe Medical Chitosan

Seed Round in 2008
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers primarily for the cosmetic and pharmaceutical sectors. Founded in 2005, the company focuses on chitin, chitosan, and their derivatives, providing high-quality raw materials that adhere to Good Manufacturing Practice (GMP) standards. In addition to conventional chitin and chitosan products, Heppe Medical Chitosan also creates nanoparticulate forms of these biopolymers, catering to diverse applications within its target industries. The company was formerly known as Katja Heppe Medical Chitosan and adopted its current name in 2006.

Nanda Technologies

Series B in 2008
Nanda Technologies was founded in 2006 in Munich. They are an international team of experienced engineers and managers from the semiconductor/high-tech industry. They are in the process of bringing their new product to the market by working together with selected lead customers.

Luphos

Seed Round in 2008
Luphos specializes in the development of ultra-high precision optical distance and topology measurement in process and quality control in industry and scientific research. It solves various different distance measurement tasks with nanometer precision in a non-contact manner. Luphos was founded in 2006.

Nanda Technologies

Venture Round in 2006
Nanda Technologies was founded in 2006 in Munich. They are an international team of experienced engineers and managers from the semiconductor/high-tech industry. They are in the process of bringing their new product to the market by working together with selected lead customers.

bubbles and beyond GmbH

Series A in 2006
Intelligent fluids GmbH, based in Leipzig, Germany, specializes in the development and production of innovative high-performance cleaning fluids. Utilizing patented technology, the company creates unique, dynamic phase fluids that achieve effective cleaning and material separation without chemical dissolving or etching, making them safer for users and the environment compared to traditional solvent-based products. Their fluids are tailored for various applications, including stripping, cleaning, and the removal of coatings in industries such as microelectronics, industrial maintenance, optics, and printing. Additionally, Intelligent fluids GmbH explores potential applications in functional skin care and dental cosmetics. The company's offerings aim to optimize processes and reduce costs while addressing ecological and economic challenges, positioning them as a leader in the transition to more sustainable cleaning solutions. Beyond its product line, Intelligent fluids GmbH also engages in joint development and private label agreements to meet specific client needs.

multiBIND

Venture Round in 2006
multiBIND biotec GmbH, founded in 2005 and based in Dortmund, Germany, specializes in developing innovative solutions for decontamination and disinfection, particularly in the fields of molecular genetics and biomedicine. The company is known for its bioDECONT technology, which effectively addresses issues related to horizontal gene transfer by removing genetic material such as DNA and RNA, along with other biomolecules like proteins and lipids. Additionally, multiBIND offers bioCLEAN, a versatile technology for antimicrobial and antiviral applications, and CleanExtract, a tool designed for the rapid assessment of microbial ATP in various challenging environments, including lubricants and industrial fluids. Through these technologies, multiBIND aims to mitigate risks associated with unwanted nucleic acid contamination, serving a range of clients in laboratories, hospitals, and industrial settings.

Particle Computer GmbH

Seed Round in 2005
Particle Computer is engaged in the development of sensor network technology solutions in Europe. It offers devices, circuits, boards, and various other parts to sense physical phenomena via sensors, compute the data on the sensor node, and to communicate the resulting information to other IT systems. Particle Computer is headquartered in Karlsruhe, Germany.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.